Published in Gut on January 01, 1997
Tumor infiltrating T lymphocytes in colorectal cancer: Tumor-selective activation and cytotoxic activity in situ. Ann Surg (2006) 1.31
Increased lysis of stem cells but not their differentiated cells by natural killer cells; de-differentiation or reprogramming activates NK cells. PLoS One (2010) 1.28
Dual functions of natural killer cells in selection and differentiation of stem cells; role in regulation of inflammation and regeneration of tissues. J Cancer (2012) 1.16
FasL is more frequently expressed in liver metastases of colorectal cancer than in matched primary carcinomas. Br J Cancer (1999) 1.06
Gene expression profiles of different clinical stages of colorectal carcinoma: toward a molecular genetic understanding of tumor progression. Int J Colorectal Dis (2005) 0.98
Expression of Fas (CD95/APO-1) ligand by human breast cancers: significance for tumor immune privilege. Clin Diagn Lab Immunol (1999) 0.97
Tumor induced inactivation of natural killer cell cytotoxic function; implication in growth, expansion and differentiation of cancer stem cells. J Cancer (2011) 0.94
Modulation of TcR/CD3-zeta chain expression by a circulating factor derived from ovarian cancer patients. Br J Cancer (2001) 0.90
Induction of Split Anergy Conditions Natural Killer Cells to Promote Differentiation of Stem Cells through Cell-Cell Contact and Secreted Factors. Front Immunol (2014) 0.90
Collaborating with the enemy: function of macrophages in the development of neoplastic disease. Mediators Inflamm (2013) 0.84
Oral cavity infection: an adverse effect after the treatment of oral cancer in aged individuals. J Appl Oral Sci (2014) 0.83
Split anergized Natural Killer cells halt inflammation by inducing stem cell differentiation, resistance to NK cell cytotoxicity and prevention of cytokine and chemokine secretion. Oncotarget (2015) 0.83
Intravenous ascorbic acid to prevent and treat cancer-associated sepsis? J Transl Med (2011) 0.81
Decreased expression of the CD3zeta chain in T cells infiltrating the synovial membrane of patients with osteoarthritis. Clin Diagn Lab Immunol (2004) 0.81
Th inducing POZ-Kruppel Factor (ThPOK) is a key regulator of the immune response since the early steps of colorectal carcinogenesis. PLoS One (2013) 0.80
Expression of CD3-zeta on T-cells in primary cervical carcinoma and in metastasis-positive and -negative pelvic lymph nodes. Br J Cancer (1999) 0.80
A lack of evidence for down-modulation of CD3 zeta expression in colorectal carcinoma and pregnancy using multiple detection methods. Clin Exp Immunol (1999) 0.78
Tumor-primed NK cells: waiting for the green light. Front Immunol (2013) 0.77
Regulation of split anergy in natural killer cells by inhibition of cathepsins C and H and cystatin F. Oncotarget (2015) 0.76
Cytotoxic T-cells and granzyme B associated with improved colorectal cancer survival in a prospective cohort of older women. Cancer Epidemiol Biomarkers Prev (2016) 0.75
Signals from lymphocytes in colon cancer. Gut (1997) 0.75
Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science (1992) 5.94
Cytotoxic T lymphocyte granules are secretory lysosomes, containing both perforin and granzymes. J Exp Med (1991) 4.15
The T cell receptor/CD3 complex is composed of at least two autonomous transduction modules. Cell (1992) 3.11
Reporting colorectal cancer. J Clin Pathol (1987) 2.50
Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma. Cancer Res (1993) 2.01
Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor. J Exp Med (1988) 1.98
Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res (1993) 1.95
Wet autoclave pretreatment for antigen retrieval in diagnostic immunohistochemistry. J Pathol (1994) 1.88
Granzymes: exogenous proteinases that induce target cell apoptosis. Immunol Today (1995) 1.76
Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res (1993) 1.61
Perforin and serine esterase gene expression in stimulated human T cells. Kinetics, mitogen requirements, and effects of cyclosporin A. J Exp Med (1989) 1.60
Role of TCR zeta chain in T cell development and selection. Science (1994) 1.59
Lymphoid infiltration and prognosis in colorectal carcinoma. Br J Cancer (1984) 1.52
Production and characterization of monoclonal antibodies raised against recombinant human granzymes A and B and showing cross reactions with the natural proteins. J Immunol Methods (1993) 1.33
Two-step TCR zeta/CD3-CD4 and CD28 signaling in T cells: SH2/SH3 domains, protein-tyrosine and lipid kinases. Immunol Today (1994) 1.32
Monoclonal antibodies reactive with the T cell receptor zeta chain: production and characterization using a new method. J Immunol (1989) 1.30
Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. Int J Cancer (1995) 1.29
Activation and signaling status of human lamina propria T lymphocytes. Gastroenterology (1991) 1.25
Clonal and frequency analyses of tumor-infiltrating T lymphocytes from human solid tumors. J Immunol (1987) 1.19
Expression of histocompatibility antigens and characterization of mononuclear cell infiltrates in normal and neoplastic colorectal tissues of humans. J Natl Cancer Inst (1985) 1.10
Immunohistological detection of human cytotoxic/suppressor T cells using antibodies to a CD8 peptide sequence. J Clin Pathol (1992) 1.07
Characterization of an immunosuppressive factor derived from colon cancer cells. J Immunol (1987) 1.04
A highly sensitive one-step method for silver intensification of the nickel-diaminobenzidine endproduct of peroxidase reaction. J Histochem Cytochem (1989) 1.02
B7 costimulation is necessary for the activation of the lytic function in cytotoxic T lymphocyte precursors. J Immunol (1995) 1.01
Expression of granzyme A and B proteins by cytotoxic lymphocytes involved in acute renal allograft rejection. Kidney Int (1995) 0.94
Immunoregulation in cancer-bearing hosts. Down-regulation of gene expression and cytotoxic function in CD8+ T cells. J Immunol (1992) 0.92
Perforin expression in lymphocytes infiltrated to human colorectal cancer. Br J Cancer (1991) 0.88
Tumor-infiltrating lymphocytes. Potential and limitations to their use for cancer therapy. Crit Rev Oncol Hematol (1992) 0.87
Density and phenotype of tumour-associated mononuclear cells in colonic carcinomas determined by computer-assisted video image analysis. Immunology (1990) 0.84
Selective immunosuppressive action of a factor produced by colon cancer cells. Cancer Res (1990) 0.84
Efficient expansion of tumor-infiltrating lymphocytes from solid tumors by stimulation with combined CD3 and CD28 monoclonal antibodies. Cancer Immunol Immunother (1993) 0.80
Use of anti-CD3 monoclonal antibody in the generation of effector cells from human solid tumors for use in cancer biotherapy. J Immunol Methods (1990) 0.78
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol (1999) 40.46
UBE3A/E6-AP mutations cause Angelman syndrome. Nat Genet (1997) 5.97
Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol (1998) 5.77
Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res (2001) 4.05
Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet (1999) 3.25
Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol (1989) 2.89
The drug resistance-related protein LRP is the human major vault protein. Nat Med (1995) 2.78
Reversible thyroid dysfunction during treatment with GM-CSF. Lancet (1991) 2.77
Potential role of molecular mimicry between Helicobacter pylori lipopolysaccharide and host Lewis blood group antigens in autoimmunity. Infect Immun (1996) 2.75
The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci U S A (1994) 2.71
Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res (1997) 2.67
Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc Natl Acad Sci U S A (1994) 2.52
Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science (1996) 2.35
Angelman syndrome: consensus for diagnostic criteria. Angelman Syndrome Foundation. Am J Med Genet (1995) 2.34
Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. Am J Gastroenterol (1995) 2.12
Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta (2002) 1.98
Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses. J Virol (2001) 1.95
Circulating V(alpha24+) Vbeta11+ NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin Immunol (2001) 1.94
Neurons but not glial cells show reciprocal imprinting of sense and antisense transcripts of Ube3a. Hum Mol Genet (2003) 1.92
Tissue distribution of the multidrug resistance protein. Am J Pathol (1996) 1.84
Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci U S A (2000) 1.83
Activated cytotoxic T cells as prognostic marker in Hodgkin's disease. Blood (1997) 1.82
Biological evidence that human papillomaviruses are etiologically involved in a subgroup of head and neck squamous cell carcinomas. Int J Cancer (2001) 1.82
Uniparental disomy explains the occurrence of the Angelman or Prader-Willi syndrome in patients with an additional small inv dup(15) chromosome. J Med Genet (1993) 1.81
A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome. Hepatology (1997) 1.79
Human papillomavirus detection and comorbidity: critical issues in selection of patients with oropharyngeal cancer for treatment De-escalation trials. Ann Oncol (2013) 1.77
Vaults are up-regulated in multidrug-resistant cancer cell lines. J Biol Chem (1998) 1.74
Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies. Cancer Res (1994) 1.73
Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res (1999) 1.72
The Fanconi anaemia gene FANCF encodes a novel protein with homology to ROM. Nat Genet (2000) 1.64
P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol (1991) 1.64
The VLA-4/VCAM-1 pathway is involved in lymphocyte adhesion to endothelium in rheumatoid synovium. J Immunol (1991) 1.63
Parietal cell protrusions and fundic gland cysts during omeprazole maintenance treatment. Hum Pathol (2000) 1.62
Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol (2000) 1.62
Expression of the serpin serine protease inhibitor 6 protects dendritic cells from cytotoxic T lymphocyte-induced apoptosis: differential modulation by T helper type 1 and type 2 cells. J Exp Med (2001) 1.62
Hypergastrinaemia during long-term omeprazole therapy: influences of vagal nerve function, gastric emptying and Helicobacter pylori infection. Aliment Pharmacol Ther (1998) 1.61
Persistence of genetically altered fields in head and neck cancer patients: biological and clinical implications. Clin Cancer Res (2001) 1.60
MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci U S A (1999) 1.59
Evidence for two pathways of meiotic intrachromosomal recombination in yeast. Proc Natl Acad Sci U S A (1989) 1.52
Rapid quantitative assessment of gastric corpus atrophy in tissue sections. J Clin Pathol (2001) 1.50
The Fanconi anemia protein FANCF forms a nuclear complex with FANCA, FANCC and FANCG. Hum Mol Genet (2000) 1.48
Evidence that leukocyte function-associated antigen-1 is involved in recirculation and homing of human lymphocytes via high endothelial venules. J Immunol (1988) 1.47
PIP2 binding residues of Kir2.1 are common targets of mutations causing Andersen syndrome. Neurology (2003) 1.46
C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2. Intensive Care Med (1993) 1.45
A cytotoxic analysis of antiseptic medication on skin substitutes and autograft. Br J Dermatol (2007) 1.45
A phase II study of human rDNA alpha-2 interferon in patients with low grade non-Hodgkin's lymphoma. Cancer Chemother Pharmacol (1986) 1.43
Unimpaired immune functions after laparoscopic cholecystectomy. Surgery (1994) 1.39
Extracellular granzymes A and B in humans: detection of native species during CTL responses in vitro and in vivo. J Immunol (1998) 1.39
Ear piercing techniques and their effect on cartilage, a histologic study. J Plast Reconstr Aesthet Surg (2007) 1.37
Familial Angelman syndrome caused by imprinted submicroscopic deletion encompassing GABAA receptor beta 3-subunit gene. Lancet (1992) 1.37
[Plastic surgery as a last resort in lichen sclerosus]. Ned Tijdschr Geneeskd (1997) 1.37
Human IP-9: A keratinocyte-derived high affinity CXC-chemokine ligand for the IP-10/Mig receptor (CXCR3). J Invest Dermatol (1999) 1.37
Parent-specific complementary patterns of histone H3 lysine 9 and H3 lysine 4 methylation at the Prader-Willi syndrome imprinting center. Am J Hum Genet (2001) 1.36
Anaplastic large-cell lymphomas of T-cell and null-cell phenotype express cytotoxic molecules. Blood (1996) 1.34
Activation of the complement system during immunotherapy with recombinant IL-2. Relation to the development of side effects. J Immunol (1990) 1.34
Regulation by glutathione of drug transport in multidrug-resistant human lung tumour cell lines overexpressing multidrug resistance-associated protein. Br J Cancer (1995) 1.32
A physical complex of the Fanconi anemia proteins FANCG/XRCC9 and FANCA. Proc Natl Acad Sci U S A (1999) 1.32
Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. J Clin Invest (2000) 1.32
Direct immunosuppressive effects of EBV-encoded latent membrane protein 1. J Immunol (2000) 1.30
Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines. Int J Cancer (1996) 1.27
Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector. J Immunol (1999) 1.26
Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients. Cancer Immunol Immunother (2005) 1.25
Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. Br J Cancer (1998) 1.23
The relation of immune depression and B-cell stimulation during the development of delayed hypersensitivity to soluble antigens. Immunology (1977) 1.23
FISH ordering of reference markers and of the gene for the alpha 5 subunit of the gamma-aminobutyric acid receptor (GABRA5) within the Angelman and Prader-Willi syndrome chromosomal regions. Hum Mol Genet (1993) 1.22
Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines. Cancer Res (2000) 1.21
Characterization of a human small cell lung carcinoma cell line with acquired resistance to cis-diamminedichloroplatinum(II) in vitro. Cancer Res (1988) 1.21
Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies. Cancer Res (2000) 1.20
Human natural killer T cells acquire a memory-activated phenotype before birth. Blood (2000) 1.20
The granzyme B inhibitor, protease inhibitor 9, is mainly expressed by dendritic cells and at immune-privileged sites. J Immunol (2001) 1.19
Drivers and barriers to patient participation in RCTs. Br J Cancer (2013) 1.19
A cluster of three GABAA receptor subunit genes is deleted in a neurological mutant of the mouse p locus. Nature (1993) 1.19
Mutation analysis of UBE3A in Angelman syndrome patients. Am J Hum Genet (1998) 1.19
Multiple human vault RNAs. Expression and association with the vault complex. J Biol Chem (2001) 1.18
The definition of the 'no change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. Eur J Cancer Clin Oncol (1988) 1.17
Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors. Am J Pathol (1996) 1.17
Granzyme-positive cytotoxic cells are specifically increased in early rheumatoid synovial tissue. Arthritis Rheum (1994) 1.17
Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer. Curr Opin Oncol (2000) 1.16
Human lymphocyte traffic assessed by indium-111 oxine labelling: clinical observations. Clin Exp Immunol (1981) 1.16
P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood (1993) 1.16
Interstitial duplication of proximal 22q: phenotypic overlap with cat eye syndrome. Am J Med Genet (1995) 1.15
A method for following human lymphocyte traffic using indium-111 oxine labelling. Clin Exp Immunol (1981) 1.15
OA1 mutations and deletions in X-linked ocular albinism. Am J Hum Genet (1998) 1.15
Sulfomucins in the human body. Biol Chem (1998) 1.15
Functional detection of MDR1/P170 and MRP/P190-mediated multidrug resistance in tumour cells by flow cytometry. Br J Cancer (1995) 1.14
Molecular and clinical study of 61 Angelman syndrome patients. Am J Med Genet (1994) 1.13
Development of sulfasalazine resistance in human T cells induces expression of the multidrug resistance transporter ABCG2 (BCRP) and augmented production of TNFalpha. Ann Rheum Dis (2004) 1.13
The vault complex. Cell Mol Life Sci (2003) 1.12
Rosette-forming cells and the immunological response after DNCB, DNP-carrier and oxazolone sensitization. Immunology (1974) 1.12
Therapy with interleukin-2 induces the systemic release of phospholipase-A2. Cancer Immunol Immunother (1995) 1.12
The value of an assessment of erythema and increase in thickness of the skin reaction for a full appreciation of the nature of delayed hypersensitivity in the guinea pig. Int Arch Allergy Appl Immunol (1977) 1.11
Production of monoclonal antibodies defining guinea pig T-cell surface markers and a strain 13 Ia-like antigen: the value of immunohistological screening. Hybridoma (1985) 1.11
Up-regulation of vaults may be necessary but not sufficient for multidrug resistance. Int J Cancer (2001) 1.10
Multidrug resistance related molecules in human and murine lung. J Clin Pathol (2002) 1.10
Expression of the multidrug resistance-associated protein (MRP) gene in human cancers. Clin Cancer Res (1995) 1.10